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Bladder cancer (BlCa) is one of the most common
malignancies of the urinary tract, with a significant
morbidity and mortality.1
Around 75–85% of the patients are diagnosed as hav-
ing nonmuscle-invasive bladder cancer (NMIBC).
Despite the treatment, these patients have a probability
of recurrence at 5 years ranging from 50 to 70% and of
progression to muscle-invasive disease of 10–15%.2
The high rate of disease recurrence of BlCa requires
lifelong surveillance in many patients, consisting of
cystoscopy, which is invasive and expensive, and
cytology, which shows poor sensitivity for low-grade
cancers.3
Cystoscopy identifies most papillary and solid lesions
but is invasive. Furthermore, cystoscopy may be incon-
clusive, false positive or negative. Urine cytology has a
reasonable sensitivity and specificity for the detection of
high-grade BlCa, whereas the sensitivity for detection
of low grade tumors ranges only from 4% to 31%.
The overall sensitivity and specificity of urine cytology
range from 7 to 100 and from 30 to 70%, respectively.4
Cystoscopy has been reported to have up to a 30% false
negative and a 17% false positive rate.5-7 Procedures
used to diagnose BlCa may include cystoscopy,
biopsy, urine cytology, and imaging test. The
estimated cost per diagnosis is about ten-fold higher
for cystoscopy compared with urine-based markers.
However, this cost-effectiveness has to be confirmed
on the basis of the biomarker ability to reduce cystos-
copy requirements.8,9
An accurate biomarker can reduce the number of the
invasive and expensive cystoscopies performed each
year. Cytology is tumor specific, but it is not very sensi-
tive. Therefore, a biomarker with better sensitivity and
comparable specificity to cytology could eventually
replace cytology and significantly improve the manage-
ment of NMIBC.Recent studies have demonstrated that long noncod-
ing RNAs (lncRNAs) play important roles in carcino-
genesis and cancer metastasis,10 and aberrant
expression of lncRNAs has been identified in BlCa,
where they may function as oncogenes or tumor sup-
pressors.11-14
In the present review, we summarize recent progress
in the application of urinary lncRNAs for the diagnosis,
assessment, and treatment of BlCa. We propose that uri-
nary lncNRAs represent a new informative tool in the
management of BlCa patients.
LITERATURE SEARCH
We searched the Medline/PubMed databases of the
National Library of Medicine for the comprehensive
information on the lncRNAs as biomarkers introduced
for BlCa. The terms used for this research included
lncRNAs, BlCa, biomarker, early detection, prognosis,
and the combinations of these words.
LONG NONCODING RNAS: BIOLOGY AND
FUNCTIONS
The ENCODE project estimated that the majority of
the genome produces .10.000 unique long noncoding
RNAs (lncRNAs),15,16 and new lncRNAs will
continue to be discovered with the advent of the
high-throughput transcriptome sequencing known as
RNA-Seq. The little translation potential due to the
presence of numerous stop codons in the RNA mature
transcript17-20 gives them the definition of nonprotein
coding transcripts, whereas the arbitrary limit of 200
bases in length distinguishes long from short
ncRNAs.21,22 According to their genomic locations
and relationship with flanking protein-coding genes,
lncRNAs are classified as 1) sense or antisense, depend-
ing on the transcription direction (same or opposite)
compared with the neighboring coding genes; 2)
intronic, when they are localized within the introns of
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and are transcribed in either orientation relative to adja-
cent protein-coding genes; 3) divergent, when they are
transcribed in the opposite direction with respect to pro-
moters of protein-coding genes; 4) intergenic, when
they are transcribed between protein-coding genes
and do not share promoters, exons or introns with
protein-coding genes. The majority of lncRNAs are
transcribed by RNA polymerase II and share properties
with coding mRNA, such as splicing and polyadenyla-
tion. In addition, most lncRNAs are exported to the
cytosol, although some are found in both cytoplasm
and nucleus. In general, lncRNAs are less conserved
and more tissue- and cell-specific than protein-coding
genes,15,23 with the exception of the members of
particular class of them named ultraconserved regions
(UCRs). These elements are transcribed as lncRNAs
from sequences of DNA 100% conserved in human,
mice, and rat genome and are often associated with
malignant states.24 The global characterization of
ncRNA functions is a crucial task and multiple
approaches have been used to identify the putative func-
tion of lncRNAs. One approach proposed by Guttman
et al.25 called guilt-by-association, is based on the asso-
ciation between expression pattern of groups of
lncRNAs in cell types and tissues and biological pro-
cesses, mRNA expression profiling data, and gene
ontology or functional pathway analyses. In this
approach, groups of lncRNAs of unknown function
are linked with groups of protein-coding mRNAs
known to be involved in a specific cellular process
based on a common expression pattern across cell types
and tissues. Thus, a positive correlation between the
expression profile of a lncRNA and mRNAs suggests
a common function in the same cellular process. For
example, lincRNA-p21 was predicted to be associated
with p53-mediated DNA damage responses. Subse-
quently, lincRNA-p21 was validated as p53 target that
modulates apoptotic responses on DNA damage.26
This approach is part of a useful tool for global predic-
tion of lncRNA function, and also provides a working
hypothesis for targeted perturbation experiments. In
addition, several studies have shown that some
lncRNAs are bound by polycomb repressive complexes
or other types of chromatin remodeling complexes and
mediate gene silencing (eg, HOTAIR, HOTAIRM1,
ANRIL, KCNQ1OT1, AIR, XIST) or activation (eg,
HOTTIP or mistral).27 Linear or circular lncRNAs
can bind microRNAs (miRNAs), thus preventing them
from regulating their mRNA targets.28-31 Several
authors30,31 provide powerful evidence that circRNAs,
covalently linked by the head-to-tail splicing of exons,
can function as miRNA sponges to suppress miRNA
activity. A circular RNA encoded as hsa_circ_001569has been determined to be significantly upregulated in
colorectal cancer tissues. Functional experiments re-
vealed a strong association of hsa_circ_001569 with
increased colorectal cancer cell proliferation and
invasion. Thus, the main function of hsa_circ_001569
was demonstrated as a circRNA sponge, by upregulat-
ing miR-145 target transcripts (E2F5, BAG4, and
FMNL2) and, subsequently, their protein amounts.32
Recent studies also revealed that circRNAs have a
great value in cancer diagnosis. Li et al33 first
discovered a significant negative correlation between
hsa_circ_002059 and gastric metastasis, indicating
their potential as novel diagnostic tools.
Furthermore, few of them can also produce small bio-
logical active peptides.34 In the last 2 years, several
studies have identified functionally important micro-
peptides translated from lncRNAs. Anderson et al.35
for instance, described a lncRNA that coded for myore-
gulin, a 46-amino acid micropeptide that reduces mus-
cle performance by inhibiting the calcium ATPase
SERCA in muscle cells. Myoregulin was derived from
a lncRNA called LINC00948 in human and
AK009351 in mouse. More recently, another lncRNA-
derived micropeptide, DWORF, which activates
SERCA to boost muscle performance, has been
described. The lncRNA responsible for this micropep-
tide is called LOC100507537 in human and NON-
MMUG026737 in mouse.36 These findings further
support the role of some RNAs, which are currently
classified as noncoding, in producing micropeptides
with biological impact.
In summary, lncRNAs participate in various mecha-
nisms including guidance of proteins to specific
genomic loci, structural roles, and as molecular decoys
in various cellular contexts.LONG NON-CODING RNAS AND BLADDER CANCER:
ABERRANT EXPRESSION AND REGULATORY
FUNCTIONS
As multiple reports suggest, lncRNAs play an impor-
tant role in urothelial carcinogenesis by modulating
cellular pathways of cell transformation. As for trans-
lated genes, they can be functionally categorized in
oncogenic or tumor-suppressor lncRNAs.37 The general
strategy to find cancer-associated lncRNAs is to
compare lncRNA expression profiles in bladder cancer
tissues with adjacent non-neoplastic tissues, using con-
ventional molecular biology techniques (eg, subtractive
suppression hybridization technique, cDNA microar-
rays, and polymerase chain reaction–based assays)
(Table I). Therefore, we can expect that more new
lncRNAs will be discovered in BlCa by using RNA-
seq technology.
Table I. Bladder cancer (BlCa) expressed long noncoding RNAs (lncRNAs): features and localization
lncRNA Location Expression Platform Sources References
HOX-AS-2 Chr7p15.2 Up qRT-PCR Urine exsosome 11
HOTAIR HOTAIR M1 Chr12q13.13 Down RIP, qRT-PCR Urine exsosome, Nonmuscle-invasive
BlCa
11,27,38
LincRNA-p21 Chr17p13.1 Down RIP, qRT-PCR BlCa 26
T-UCR 81 Chr1p36.22 Up qRT-PCR, ISH BlCa 29
UCA1
UCA1a
Chr19p13.12 Up Subtractive
Hybridization, PCR
BlCa, urine sediments 39-42
H19 Chr11p15.5 Up PCR BlCa 14,43-46
NEAT1 Chr11q13.1 Up PCR BlCa 44
Linc-UBC1 Chr1q32.1 Up Microarray, qRT-PCR Invasive bladder cancer 47
MALAT-1 Chr11q13.1 Up PCR BlCa, urine exsosome 48,49
TUG1 Chr22q12.2 Up qRT-PCR Bladder urothelial carcinoma 50,51
UNMIBC Chr1p31.1 Up RIP, qRT-PCR NMIBC 52
PVT1 Chr8q24.21 Up qRT-PCR BlCa 53
ncRAN Chr17q25.1 Up qRT-PCR BlCa 54
PCA-T Chr8q24.21 Up qRT-PCR BlCa 55
GHET 1 Chr7q36.1 Up qRT-PCR BlCa 56
SPRY4-IT1 Chr5q31.3 Up qRT-PCR BlCa 57
MEG3 Chr14q32.3 Down qRT-PCR BlCa 58-60
GAS 5 Chr1q25.1 Down qRT-PCR BlCa 61
Abbreviations: GAS 5, growth arrest-specific 5; GHET 1, gastric carcinoma highly expressed transcript 1; MALAT-1, metastasis-associated lung
adenocarcinoma transcript 1;MEG3, maternally expressed gene 3; ncRNA, noncoding RNA; NEAT 1, nuclear paraspeckle assembly transcript
1; TUG1, taurine-upregulated gene 1; UBC1, upregulated in bladder cancer 1; UCA1, urothelial cancer associated-1; UNMIBC, upregulated in
nonmuscle-invasive bladder cancer.
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BLADDER CANCER
Similar to protein-coding oncogenes, lncRNAs with
oncogenic function are more expressed in tumor cells
compared with the normal ones Fig 1. For example,
the lncRNA urothelial cancer associated-1 (UCA1) of
1442 bp in length has been screened and cloned from
the human bladder (transitional cell carcinoma, TCC)
cell line BLZ-211.39 UCA1 is highly specific in BlCa
and in embryonic tissues, but not in adult tissues or adja-
cent non-neoplastic tissues, indicating that UCA1 may
be involved in embryonic development and reactivated
during adult tumourigenesis. Furthermore, after exoge-
nous UCA1 expression in BLZ-211 bladder cell lines,
the proliferation, migration, invasion, and drug resis-
tance behaviors were increased. In addition, when
BLZ-211 cells-expressing UCA1 were inoculated into
nude mice, their capacity of tumor formation was
increased,39 suggesting that UCA1 has a pivotal onco-
genic role in BlCa development. Recently, it has been
proven that UCA1 confers resistance to cisplatin/gemci-
tabine via activating miR-196a-5p through the tran-
scription factor CREB in bladder cancer cells and in a
xenograft mouse model.40-42 lncRNA H19 is one of
the first discovered noncoding RNAs in mammalian
genome43; it has been found to be highly expressed in
human embryos and fetal tissues, whereas its expression
is completely lost in adults.44 It is re-expressed in anumber of tumors, including bladder carcinoma,
demonstrating that it is an onco-fetal RNA.44 In partic-
ular, H19 expression levels were remarkably increased
in bladder cancer tissues as compared with adjacent
normal control tissues.14,45,46 The ectopic expression
of H19 promotes bladder cancer cell proliferation
in vitro14 and enhances bladder cancer cell migration,
both in vitro and in vivo.45 On the basis of these find-
ings, H19 appears to be an onco-lncRNA and serves
as tumor marker in BlCa. More recently, a new lncRNA,
linc-UBC1 (upregulated in bladder cancer 1) was found
to be up regulated in 60% of invasive bladder cancer
tissues and physically associated with polycomb repres-
sive complexes 2 complex to regulate histone modifica-
tion status of target genes.47 MALAT1 (metastasis-
associated lung adenocarcinoma transcript 1) was the
first to be characterized in metastatic small cell lung
cancer,48 but recent studies showed that MALAT1 is
also upregulated in BlCa, and its expression levels
correlate with tumor grade and metastatic stage.49,50
MALAT1 is highly conserved among mammals
(MALAT1) and in bladder cancer cells, which is able
to promote epithelial-mesenchimal transition and sub-
sequent cell migration, by activating the Wnt/b-catenin
signaling pathway.50 Taurine-upregulated gene 1
(TUG1; also known as TI-227H; Linc00080;
ncRNA00080) was initially detected in a genomic
screen for genes in response to taurine treatment in
Fig 1. LncRNAs involved in bladder cancer progression. (A)Graphical description of a sagittal view of the bladder
wall showing the progression of lesions associated with the staging of BlCa according to the tumor-node-metastasis
(TNM) system. (B) Schematic representation of deregulated lncRNAs described in themanuscript and their expres-
sion correlated to grading, according to 2004WHO/International Society of Urological Pathology (ISUP) criteria.
Papillary urothelial neoplasm of low malignant potential (PUNLMP) is equivalent to grade 1 of the older system
(1973 World Health Organization [WHO]). NBE, normal bladder epithelium.
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vations, expression levels of TUG1 have been found to
be deregulated in a large panel of tumors including
BlCa. In particular, TUG1 was found upregulated in
bladder urothelial carcinoma compared with paired
normal urothelium, and high expression levels of
TUG1 were associated with high grade and stage carci-
nomas. More recently, it has been observed that TUG1
levels were significantly increased in metastatic tumors
and were associated with shorter overall survival of
MIBC patients. TUG1 silencing in vitro led to a
decrease in cancer cell proliferation and a reduction in
migration capacity of cancer cells.51 The expression
levels of TUG1 were upregulated in bladder urothelial
carcinoma compared with paired normal urothelium.
High TUG1 expression levels were associated with
high grade and stage carcinomas. Cell proliferation in-
hibition and apoptosis induction were observed in
TUG1 siRNA-transfected bladder urothelial carcinoma
T24 and 5637 cells.52 The lncRNA termed lncRNA-
UNMIBC (upregulated in nonmuscle-invasive bladder
cancer) was evaluated in NMIBC compared withnormal mucosa. The upregulation of this lncRNA has
been associated with tumor growth and may indicate a
negative prognostic factor of recurrence.53 More
recently, it has been demonstrated that noncoding
RNA transcripts originate from UCRs, named tran-
scribed ultraconserved regions (T-UCRs), have
different expression profiles and play functional roles
in the pathophysiology of multiple cancers. By using a
microarray approach, it has been identified the
ultraconserved RNA (uc.) 81 as the most upregulated
T-UCR in BlCa tissues, although its expression was
lower than the one in pericancerous bladder tissues.29
In addition, in vitro experiments, evaluating the effects
of uc.81 silencing, showed significant decreased capac-
ities for bladder cancer cell invasion, migration, and
proliferation. Plasmacytoma variant translocation gene
lncRNA (PVT-1) is an oncogene encoding a lncRNA,
which maps to chromosome 8q24. It has been demon-
strated that PVT1 is upregulated in bladder cancer tis-
sues and cells, functioning as an oncogene. Its silence
suppresses proliferation of bladder cancer cells. In addi-
tion, shRNA sequences, targeting PVT1 controlled by
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expression of PVT1 in response to different concentra-
tion of doxycycline and inhibited progression of BlCa.54
Nuclear paraspeckle assembly transcript 1 (NEAT1) is
an lncRNA that is specifically present in the para-
speckles. NEAT1 has been demonstrated to be involved
in several cancers. A recent study describes that NEAT1
is highly expressed in bladder cancer tissues compared
with the matched tissues and in bladder cancer cell lines
compared with the normal bladder epithelial cells. It has
been shown that the inhibition of NEAT1 suppresses
cell proliferation, migration and induces apoptosis,
thus supporting its oncogenic role.44 ncRAN (noncod-
ing RNA expressed in aggressive neuroblastoma) also
plays an important role in bladder cancer cells growth
and invasion. ncRAN, also named SNHG16 (snoRNA
host gene 16), is overexpressed in BlCa and positively
correlates with aggressiveness. The silencing of
SNHG16 can improve chemotherapy sensitivity in
BlCa cell lines.55 Prostate cancer–associated transcript
1 (PCAT-1) is a lncRNA that promotes cell proliferation
in prostate cancer. More recently, it has been demon-
strated that PCAT-1 also plays a role in BlCa. PCAT-1
was found to be upregulated in BlCa compared with
paired normal urothelium. Cell proliferation inhibition
and apoptosis induction were also observed in PCAT-1
small hairpin RNA (shRNA)-transfected bladder cancer
T24 and 5637 cells. Data suggest that PCAT-1 plays
oncogenic roles in human BlCa.56
Another lncRNA, gastric carcinoma highly expressed
transcript 1 (GHET1), has recently been shown to act as
an oncogenic ncRNA. GHET1 is upregulated in bladder
cancer tissues as compared with adjacent normal tissues
and is correlated with tumor size, advanced tumor,
lymph node status, and poor survival. GHET1 knock-
down suppresses the proliferation and invasion of
bladder cancer cells, and the inhibition of GHET1
expression reverses the epithelial-mesenchimal transi-
tion in bladder cancer cells.57 Protein sprouty homolog
4 lncRNA (SPRY4-IT) (708 bp) is a lncRNA derived
from an intronic region within the SPRY4 gene.
SPRY4-IT1 has been found to be upregulated in esoph-
ageal squamous cell carcinoma and breast cancer, sug-
gesting that SPRY4-IT1 has a tissue-specific
expression pattern and may function as oncogene or tu-
mor suppressor in different cancers. SPRY4-IT1 expres-
sion has been found to be increased in bladder
cancer tissues, and SPRY4-IT1 levels were highly posi-
tively correlated with histological grade, tumor stage,
and lymph node metastasis and reduced overall sur-
vival. In addition, in vitro assays show that the suppres-
sion of SPRY4-IT1 expression in bladder cancer cells
significantly inhibits cell proliferation, migration, and
invasion.58LNCRNAS WITH TUMOR-SUPPRESSOR FUNCTION IN
BLADDER CANCER
A tumor suppressor lncRNA is identified as a gene
whose product normally inhibits tumor initiation and
progression. Accordingly, a tumor suppressor lncRNA
is downregulated or not expressed in cancer tissues.
Maternally expressed gene 3 (MEG3) is an imprinted
gene that encodes for a lncRNA expressed in many
normal tissues, whereas its expression is lost in an ex-
panding list of primary human tumors and tumor cell
lines as well as in BlCa.59 Multiple mechanisms
contribute to the tumor suppressive roles of MEG3,
including gene deletion, promoter hypermethylation,
and hypermethylation of the intergenic, differentially
methylated region.60 The re-expression of MEG3 in-
hibits tumor cell proliferation in culture and the colony
formation in soft agar. The underlying mechanism of
growth inhibition is partly the result of MEG3-
induced apoptosis.61 Moreover, a recent study has
identified that low expression of serumMEG3 in BC pa-
tients, was associated with poor recurrence-free sur-
vival.62
LncRNA-growth arrest-specific (GAS) 5 has been
found downregulated in BlCa as compared with adja-
cent normal tissues. Knocking down GAS5 expression
promotes bladder cancer cell proliferation, whereas
the overexpression of GAS5 suppresses cell prolifera-
tion. Furthermore, GAS5 knockdown results in an
increased percentage of cells in S and G2 phase, and
in a decreased percentage of cells in G1 phase, via regu-
lation of chemokine (C-C motif) ligand 1 expression.63APPLICATIONS OF LONG NON-CODING RNAS AS
URINARY BIOMARKERS FOR NON-MUSCLE INVASIVE
BLADDER CANCER
Bladder tumor markers are secreted in urines and
many are tumor cell-associated and can be detected by
analyzing exfoliated cells in urine specimens.
An ideal urine marker for BlCa should be noninva-
sive, easy to interpret, and possess high sensitivity and
specificity not only for the diagnosis but also for the
reduction of the number of cystoscopies in surveillance
of NMIBC.
In the last few years, as more lncRNAs have been
discovered and their biological functions clarified, the
lncRNAs have been increasingly proposed as important
diagnostic and prognostic biomarkers64 for BlCa.
NcRNAs are relatively stable in cells present in urines
and their expression in cells isolated from voided urines
of BlCa patients has been recently proposed as a nonin-
vasive diagnostic assay.65
Approximately 50 ml of urine is spun at 1700g for
10 min to pellet exfoliated cells. The pelleted material
Table II. Detailed characterization of available data on potential biomarkers
Ref N Cases N control Validation Results replication
Zhang et al, 201242 94 144 RT-PCR Yes (73)
Wang et al, 200637 94 85 RT-PCR Yes (70)
Srivastava et al, 201471 117 74 RT-PCR Yes (37, 70)
Zhou et al, 200641 85 10 RT-PCR Yes (11, 51)
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the suspension using commercially available Kit, ac-
cording to manufacturer’s instructions.66 Urine is
increasingly studied as it can be obtained noninvasively
in large volumes and contains exosomes (UEs) vesicles
with diagnostic potential67 for urological cancers.68,69
Urinary lncRNAs can be durably detected in urines.66
Moreover, RNA is protected by urinary UEs to a
greater degree than by cells in urines,70 and the UEs
themselves are remarkably stable.41 Several reports
characterized the performance of lncRNA as potential
urinary biomarkers in BlCa (See Table II for details).
Zhang et al42 evaluated the potential application of
UCA1 in urinary sediments from patients with BlCa,
and they found that it is particularly valuable for super-
ficial G(2)-G(3) patients at a high risk for muscular in-
vasion with a sensitivity of 86.4% and 92.3%,
respectively. UCA1 seems to be a new promising uri-
nary marker for the diagnosis of BlCa. Accordingly,
Eissa et al72 demonstrated that lncRNA-UCA1 has
good sensitivity and specificity (91.5 and 96.5%,
respectively) for distinguishing BlCa patients from
non-BlCa ones.
Some authors72,73 analyzed the mRNA expression of
UCA1 in exfoliated cells in the urines of TCC cases of
UBC, finding that UCA1 mRNA expression in TCC-
exfoliated cells is not significantly correlated with the
clinical characteristics such as patient’s age, sex, nodal
status, and smoking habits. However, their results indi-
cated that urinary UCA1 gives higher positive results in
comparison to cytology, particularly in nonmuscle-
invasive low-grade disease. Accumulation of UCA1 in
urine sediments could be used as a sensitive and specific
diagnostic and follow-up marker for patients with tran-
sitional cell carcinoma.
Urine is an excellent source of UEs, 30–150 nM
membrane-bound secreted vesicles that represent an
excellent source for biomarker discovery.38,74
Interestingly, UEs are markedly depleted in mRNA
but enriched in lncRNAs75 and lncRNAs show greater
specificity than protein-coding mRNA as biomarkers
of cancer.15 Bladder cancer–associated lncRNAs have
been isolated from voided cells or free floating in urines.
However, no published studies have demonstrated that
bladder cancer UE–derived lncRNAs can serve as uri-
nary biomarkers yet.72 One benefit of using UEs isthat the exosome membrane protects the contents
from proteases and RNAses, which are ubiquitous in
urines.41 Recently, Berrondo et al11 showed that HO-
TAIR and several tumor-associated lncRNAs are en-
riched in UEs from UBC patients with high-grade
muscle-invasive disease (HGMI pT2-pT4).
Martinez-Fernandez et al76 previously investigated
the possibility that HOTAIR expression could serve as
a prognostic marker for disease recurrence in NMIBC,
demonstrating that patients with higher levels of HO-
TAIR expression also have earlier recurrence of disease.
In addition, they used The Cancer Genomic Atlas data
set for bladder cancer to show that HOTAIR expression
is correlated with stage of UBC, with the most invasive
T4 tumors having the highest level of HOTAIR expres-
sion. Given the importance of HOTAIR in bladder tu-
mor progression, there is increased interest in using
HOTAIR as a biomarker. Importantly, having a noninva-
sive way to detect HOTAIR in cancer patients, such as
UEs, would be ideal for biomarker development.
Further studies are encouraged to assess the clinical util-
ity of UEs HOTAIR content in the management of
NMIBC cancer. Furthermore, Berrondo et al11 also
showed that HOX-AS-2, MALAT1, and other lncRNAs
are enriched in UEs from UBC patients with HGMI dis-
ease (pT2-pT4 on final cystectomy pathology). There-
fore, UEs seems to be an amenable field of research
for lncRNAs as urinary biomarkers in BlCa.CONCLUSIONS AND FUTURE PERSPECTIVES
Several bladder urinary tumor markers such as BTA,
NMP22, FDP, ImmunoCyt, and FISH (UroVysion)77
have been developed and approved by FDA for their
use in initial diagnosis, monitoring recurrence, and
treatment response. The impetus for developing new
bladder tumor markers comes from the low effective-
ness and invasive nature of cystoscopy and cytology
in the management of BlCa patients. Moreover, the uri-
nary markers, currently used, have shown higher sensi-
tivity as compared with cytology, but often they show
low specificity.
Literature data collectively indicated the high tissue-
and cancer-specific expression of lncRNAs,78,79
suggesting their diagnostic and prognostic potential in
urologic malignancies.
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tial biomarkers in urine samples. In BlCa, UCA1 (ur-
othelial carcinoma associated 1) transcript detected in
urines has shown to be a highly sensitive and specific
biomarker of bladder carcinoma.73 However, the most
famous example of such biomarkers is PCA3 in pros-
tate cancer. PCA3 was identified in 1999 as highly
overexpressed in almost all prostate cancer tissue
specimens, compared with normal or hypertrophied
tissue. A PCA3 score, based on the ratio of PCA3
mRNA over PSA mRNA, can be calculated starting
from a urine sample collected after digital rectal ex-
amination. PCA3 score has been demonstrated to be
a more specific predictor of prostate cancer diagnosis
compared with the commonly used prostate-specific
antigen (PSA).80-83
Novel lncRNAs are increasingly being identified to
help prognosticate patients with BlCa.More than 30 uri-
nary biomarkers have been reported for use in BlCa
diagnosis, but only a few are commercially available,
such as BTA and NMP22.84
To date, the only one study71 on diagnostic and prog-
nostic utility of lncRNA as urinary bladder tumor
marker concludes that UCA1 mRNA is a better nonin-
vasive biomarker for diagnosis of nonmuscle-invasive
low-grade UBC, as compared with the cytology. It
may be used in combination with cytology for noninva-
sive diagnosis of UBC and may increase the interval
between monitoring cystoscopy and replacing cystos-
copies all together. Further investigations will be
encouraged on the UEs, that may represent a noninva-
sive promising way to detect lncRNAs in cancer pa-
tients, as shown by HOTAIR evidence.11 The widely
used commercial microarray platforms in addition to
protein coding mRNAs were designed to detect tran-
scripts such as ncRNAs, providing a valuable resource
for the identification of novel biomarkers based on miR-
NAs and lncRNAs. Deep sequencing technology is
currently becoming cheaper and more widely acces-
sible, so it is likely that an explosive growth of newly
identified lncRNAs differentially expressed in cancers
and associated with various clinical outcomes, will be
discovered.
In conclusion, the rapidly expanding catalogue of
lncRNAs has highlighted their potential value as tumor
markers in patient diagnosis and prognosis and holds
promises that in the near future lncRNAs will become
even more important in cancer patient management.ACKNOWLEDGMENTS
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